BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Atienza-Mateo B, Remuzgo-Martínez S, Prieto-Peña D, Mora Cuesta VM, Iturbe-Fernández D, Llorca J, Sánchez-Bilbao L, Corrales A, Blanco Rodríguez G, Gómez-Román JJ, Cifrián JM, González-Gay MÁ. Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review. J Clin Med 2020;9:E3070. [PMID: 32977717 DOI: 10.3390/jcm9103070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Wang Y, Li L. Rituximab for connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis. Int J Rheum Dis 2023;26:225-35. [PMID: 36378118 DOI: 10.1111/1756-185X.14495] [Reference Citation Analysis]
2 Pulito-Cueto V, Genre F, López-Mejías R, Mora-Cuesta VM, Iturbe-Fernández D, Portilla V, Sebastián Mora-Gil M, Ocejo-Vinyals JG, Gualillo O, Blanco R, Corrales A, Ferraz-Amaro I, Castañeda S, Cifrián Martínez JM, Atienza-Mateo B, Remuzgo-Martínez S, González-Gay MÁ. Endothelin-1 as a Biomarker of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Associated with Autoimmune Diseases. Int J Mol Sci 2023;24. [PMID: 36674789 DOI: 10.3390/ijms24021275] [Reference Citation Analysis]
3 Wu D, Luo Y, Li T, Zhao X, Lv T, Fang G, Ou P, Li H, Luo X, Huang A, Pang Y. Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment. Front Immunol 2022;13:1051082. [PMID: 36618407 DOI: 10.3389/fimmu.2022.1051082] [Reference Citation Analysis]
4 Liossis SC, Bounia CA. Treating Autoimmune-Related Interstitial Lung Disease With B Cell Depletion. Front Med 2022;9:937561. [DOI: 10.3389/fmed.2022.937561] [Reference Citation Analysis]
5 Bryl E. B cells as target for immunotherapy in rheumatic diseases - current status. Immunol Lett 2021;236:12-9. [PMID: 34077805 DOI: 10.1016/j.imlet.2021.05.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Kapuczinski A, Cotils M, Gombeir Y. Successful treatment of interstitial pneumonia with autoimmune features using rituximab as salvage therapy. Clin Case Rep 2021;9:e04180. [PMID: 34026182 DOI: 10.1002/ccr3.4180] [Reference Citation Analysis]
7 Vicente-Rabaneda EF, Atienza-Mateo B, Blanco R, Cavagna L, Ancochea J, Castañeda S, González-Gay MÁ. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review. Autoimmun Rev 2021;20:102830. [PMID: 33887489 DOI: 10.1016/j.autrev.2021.102830] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
8 Cassone G, Sebastiani M, Vacchi C, Erre GL, Salvarani C, Manfredi A. Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review. Drugs Context 2021;10:2020-8-8. [PMID: 33505480 DOI: 10.7573/dic.2020-8-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]